CAMP4 Therapeutics Corporation Increase (Decrease) in Prepaid Expense and Other Assets
CAMP4 Therapeutics Corporation (CAMP) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$333.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-13
- CAMP4 Therapeutics Corporation increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $641.00K.
- CAMP4 Therapeutics Corporation increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$974.00K, a 14014.29% decline year-over-year.
- CAMP4 Therapeutics Corporation increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $779.00K, a 111.68% increase year-over-year.
- CAMP4 Therapeutics Corporation increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $419.00K.
- CAMP4 Therapeutics Corporation increase (decrease) in prepaid expense and other assets for fiscal 2025 was $888.00K, a 24.89% increase from fiscal 2024.
- CAMP4 Therapeutics Corporation increase (decrease) in prepaid expense and other assets for fiscal 2024 was $711.00K, a 69.29% increase from fiscal 2023.
- CAMP4 Therapeutics Corporation increase (decrease) in prepaid expense and other assets for fiscal 2023 was $420.00K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $641.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$333.00K 10-Q · filed 2026-08-13 | $446.00K derived: sum of 3 quarters · filed 2026-08-13 | $865.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$974.00K 10-Q · filed 2026-05-07 | -$195.00K derived: sum of 2 quarters · filed 2026-05-07 | $224.00K derived: sum of 3 quarters · filed 2026-05-07 | -$93.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $779.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.20M derived: sum of 2 quarters · filed 2026-03-05 | $881.00K derived: sum of 3 quarters · filed 2026-08-13 | $888.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $419.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $102.00K derived: sum of 2 quarters · filed 2026-08-13 | $109.00K 10-Q · filed 2025-11-06 | $477.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$317.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$310.00K 10-Q · filed 2026-08-13 | $58.00K derived: sum of 3 quarters · filed 2026-08-13 | -$145.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $7.00K 10-Q · filed 2026-05-07 | $375.00K derived: sum of 2 quarters · filed 2026-05-07 | $172.00K derived: sum of 3 quarters · filed 2026-05-07 | -$480.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $368.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $165.00K derived: sum of 2 quarters · filed 2026-03-05 | -$487.00K derived: sum of 3 quarters · filed 2026-03-05 | $711.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | -$203.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$855.00K derived: sum of 2 quarters · filed 2025-11-06 | $343.00K 10-Q · filed 2025-11-06 | $430.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$652.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $546.00K 10-Q · filed 2025-08-14 | $633.00K derived: sum of 3 quarters · filed 2025-08-14 | |
| 2024-03-31 | $1.20M 10-Q · filed 2025-05-13 | $1.28M derived: sum of 2 quarters · filed 2025-05-13 | ||
| 2023-12-31 | $87.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $420.00K 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $333.00K 10-Q · filed 2024-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |